Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Savaysa,lixiana
Synonyms :
edoxaban
Class :
Factor Xa inhibitors
Brand Name :
Savaysa,lixiana
Synonyms :
edoxaban
Class :
Factor Xa inhibitors
Dosage Forms & StrengthsÂ
TabletÂ
15mg,30mg,60mgÂ
After 5-10 days of initial treatment with a parenteral anticoagulant:
60
mg
Tablet
Orally 
every day
After 5-10 days of initial treatment:
≤60kg:30mg orally every day >60kg:60mg orally every day
Dose Adjustments
Renal impairment (PE/DVT)
15-50ml/min-30mg orally every day
>50ml/min-No dosage adjustment needed
Renal impairment (Atrial fibrillation)
CrCl<15ml/min: No data available
CrCl 15-50ml/min:30mg orally every
day
CrCl>50-95ml/min: Dosage adjustment not necessary
CrCl>95ml/min: Not recommended
may enhance the effects of the other by pharmacodynamic synergism
may increase the adverse effect of nonsteroidal anti-inflammatory agents
may increase the adverse effect of nonsteroidal anti-inflammatory agents
may increase the adverse effect of nonsteroidal anti-inflammatory agents
may increase the adverse effect of nonsteroidal anti-inflammatory agents
may increase the adverse effect of nonsteroidal anti-inflammatory agents
edoxaban: it may enhance the toxic effect of Nonsteroidal Anti-Inflammatory Agents
edoxaban: it may enhance the toxic effect of Anti-Inflammatory Agents
edoxaban: it may enhance the toxic effect of Anti-Inflammatory Agents
edoxaban: it may enhance the toxic effect of Anti-Inflammatory Agents
may increase the toxic effect of anti-platelet agents
may increase the toxic effect of aspirin
may have an increasingly adverse effect when combined with edoxaban
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increases the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the toxicity through anti-coagulation
may increase the toxicity of each other through anti coagulation
may decrease the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may enhance the toxicity of the other through anti coagulation
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may decrease the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may enhance the toxicity of the other through anti coagulation
edoxaban increases the effect of anticoagulants
edoxaban increases the effect of anticoagulants
edoxaban increases the effect of anticoagulants
edoxaban increases the effect of anticoagulants
edoxaban increases the effect of anticoagulants
lapatinib increases the level of effectiveness of edoxaban through P-glycoprotein MDR1 efflux transporter
may increase the anti-coagulant action of anti-coagulants
may enhance the toxicity of the other through anti coagulation
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may enhance the toxicity of the other through anti coagulation
may enhance the toxicity of the other through anti coagulation
may enhance the toxicity of the other through anti coagulation
may enhance the toxicity of the other through anti coagulation
may enhance the toxicity of the other through anti coagulation
may enhance the toxicity of the other through anti coagulation
may enhance the toxicity of the other through anti coagulation
may enhance the toxicity of the other through anti coagulation
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may have an increasingly adverse effect when combined with Edoxaban
may have an increasingly adverse effect when combined with Edoxaban
may have an increasingly adverse effect when combined with Edoxaban
may have an increasingly adverse effect when combined with Edoxaban
may have an increasingly adverse effect when combined with Edoxaban
may decrease the therapeutic effect when combined with anticoagulants
may decrease the therapeutic effect when combined with anticoagulants
may decrease the therapeutic effect when combined with anticoagulants
may decrease the therapeutic effect when combined with anticoagulants
may decrease the therapeutic effect when combined with anticoagulants
It may enhance the effect when combined with lonafarnib by affecting the P-glycoprotein efflux transporter
When edoxaban is used together with sertraline, the risk or seriousness of bleeding may be enhanced
When edoxaban is used together with andrographolide, this leads to enhanced risk or seriousness of bleeding
antiplatelet agents increase the toxicity of edoxaban
antiplatelet agents increase the toxicity of edoxaban
may enhance the serum concentration
may increase the anticoagulant effect of Anticoagulants
the risk of bleeding may be increased
Frequency defined:Â Â
1-10%Â
AnemiaÂ
Abnormal LFTÂ
RashÂ
<1%Â
Lung diseaseÂ
Fatal bleedingÂ
Gastrointestinal bleedingÂ
Major bleedingÂ
Post-marketing reportsÂ
HeadacheÂ
DizzinessÂ
Abdominal painÂ
Pregnancy consideration: Insufficient data availableÂ
Pregnancy category: Not assignedÂ
Lactation: The drug is not excreted in the breast milkÂ
Pregnancy category:Â
Patient information leafletÂ
Generic Name: edoxabanÂ
Pronounced: [e-DOX-a-ban]Â
Why do we use edoxaban?Â
It is used to treat Deep vein thrombosis (DVT), a form of the blood clot and pulmonary embolismÂ
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
